Who Owns Nexon Pharma?

Nexon Pharma Sp. z o.o. was entered in the National Court Register on December 13, 2016, with its registered office in Warsaw and initial share capital of PLN 5,000. The company was established by three individual shareholders rather than spun out of a larger pharmaceutical group.

Its registered primary business activity is the production of homogenized food and dietetic products, reflecting a supplements-oriented rather than prescription-drug model. The related entity Nexon Pharma Spolka z ograniczona odpowiedzialnoscia sp.k., a limited partnership sharing the same address, was registered shortly after with its own tax number.

The company's stated mission is family health: supplements and medical devices based on proven formulations, sold at accessible prices. Its go-to-market decision was deliberate: products are sold exclusively through pharmacies, positioning the brand inside the healthcare channel rather than mass retail.

The product portfolio grew around several anchor lines. Mediprolac, a probiotic-style supplement family, expanded into variants for children, immune support, and drop formats. The Islandzki Medic+ line covers Icelandic-moss-based throat syrup, spray, and lozenges classified as medical devices. Euphrasia-branded eye drops address the eye care segment. A vitamin range covers C, D3, D3 plus K2, B12, and B Complex, alongside specialty products such as Biotyna Multi Max, Calm Control Sen, and Lipiredox K Plus.

Alongside its own brands, the company describes group capabilities in pharmaceutical warehousing and distribution, market analysis for the pharmacy sector, and contract manufacturing support for third-party brands, citing roughly 20 years of group experience in sales to hospitals, wholesalers, and pharmacies.